A matched case-control study of nearly 100 women details the reduced effect of anti-obesity medications in those with a history of breast cancer and aromatase inhibitor use.
An analysis of data from the CLEAR Outcomes trial presented at ENDO 2023 suggests use of the non-statin lipid-lowering agent provided cardiovascular risk reduction comparable to statin therapy for each 1.0 mmol/L reduction in LDL-C.
No significant differences in cardiovascular outcomes among patients receiving different GLP-1 agonists including exenatide extended-release, exenatide immediate-release, liraglutide, albiglutide, and dulaglutide.
Bradley Miller, MD, University of Minnesota Academic Health Center hopes the team learns â€œgood informationâ€ about how kids are growing on this dose of somavaratan that will then be confirmed in the phase 3 head-to-head with growth hormone daily.
Although there are several unanswered questions in the field of menopause, but Cynthia Stuenkel, MD, University of California San Diego explained that many experts are beginning to understand the idea of hot flashes and how early and late they can occur in women.
The DIaMonD and GOLD Studies, which used continued glucose monitoring (CGM) in patients with type 1 diabetes who were in less than optimal control showed that the addition of CGM to these patientsâ€™ self-monitoring of blood glucose contributed to lower A1C, more time spent in range, less hypoglycemia, less severe hyperglycemia, and better quality of life.
Does early-life environmental exposure to BPA (Bisphenol A) affect gene expression linked to fatty liver? That's the question Lindsey S. Trevino, PhD, Baylor College of Medicine and team sought to answer in their study using rat models.